Cart
0

Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, and Artificial Pancreas), Demographic [Adult Population (>14 years) & Child Population (<14 years)], Indication (Type 1 Diabetes & Type 2 Diabetes), and End Users (Diagnostics/Clinics, ICUs, and Home Healthcare) - Global Opportunity Analysis and Industry Forecast, 2014-2023

Get 20% Free Customization In This Report
LI_172098
Pages: 140
Apr 2017 | 2564 Views
 
Author's : Onkar Sumant and Tenzin Kunsel
Tables: 50
Charts: 25
 

Next Generation Diabetes Therapy and Drug Delivery Market Overview:

Global Next Generation Diabetes Therapy and Drug Delivery Market was valued at $617 million in 2015 and is expected to garner $9,673 million by 2022, registering a CAGR of 41.1% during the forecast period 2016 2023. The next generation diabetes therapy and the drug delivery devices are the advanced form of diabetic products that improve the quality of life of diabetic patients. Oral and inhalable insulin introduce a different mode of insulin delivery in diabetic patients, and are a painless mode of introducing insulin than the injectable insulins, reducing the risk of skin irritation caused due to needles. In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. Advanced diabetic therapy in the form of insulin patches, continuous glucose monitoring systems (CGMS), and artificial pancreas helps to improves management of blood sugar level and reduces the risk of any diabetic-related complications.

Global Next Generation Diabetes Therapy And Drug Delivery Market Segmentation

Next Generation Diabetes Therapy and Drug Delivery Market Segmentation

Get more information on this report : Request Sample Pages

The global next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, end user, and geography. Based on product type, it is classified into inhalable insulin, oral insulin, insulin patches, CGM systems, and artificial pancreas. Based on demographics, it is bifurcated into adult population (>14 years) and child population (14 years). Based on indication, it is divided into type 1 diabetes and type 2 diabetes. Based on end users, it is categorized into diagnostics/clinics, ICUs, and home healthcare. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The market is expected to witness an exponential growth during the forecast period, owing to the benefits of using these advanced devices over conventional products and rise in the healthcare expenditure. Furthermore, the rise in the incidence of diabetes globally and increase in the disposable income among the diabetic patients are expected to boost the market growth. However, lack of awareness, cost restrains in the developing regions, and less variability in products are expected to hamper this growth. Development of affordable products with fewer side effects and presence of undiagnosed diabetic patients globally are expected to provide opportunities for the market growth.

The key players profiled in this report include Abbott Laboratories, Medtronic, Inc., Sanofi, Novo Nordisk, MannKind Corporation, Enteris BioPharma, Dexcom, Inc., Senseonics Holding, Inc., Medtech, and Johnson & Johnson.

Other players in the value chain include Synertech, Zosano Pharma Corp., Relmada Therapeutics, Inc., Eli Lilly and Company, and Transdermal Specialties Inc.

Next Generation Diabetes Therapy And Drug Delivery Market, By Geography, 2014-2023 ($Million)

Next Generation Diabetes Therapy And Drug Delivery Market By Geography

Get more information on this report : Request Sample Pages

Asia-Pacific possesses high market potential for the growth of next generation diabetes therapy and drug delivery market, owing to increase in demand for advanced diabetic products, high incidence of diabetes, and rise in healthcare expenditure. It has experienced fast-paced growth, in terms of production and development of advanced diabetic products.

South Korea Next Generation Diabetes Therapy And Drug Delivery Market, 2014-2023 ($Thousand)

South Korea Next Generation Diabetes Therapy and Drug Delivery Market

Get more information on this report : Request Sample Pages

South Korea market is projected to grow at a high CAGR of 49.7% during the forecast period.

Key Benefits:

  • This report entails a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities.
  • Market estimations are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to product type, demographics, end users, and geography.
  • In-depth analysis based on geography assists in understanding the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.

Next Generation Diabetes Therapy And Drug Delivery Market Key Segments:

By Product Type

  • Inhalable Insulin
  • Oral Insulin
  • Insulin Patches
  • CGM Systems
  • Artificial Pancreas

By Demographic

  • Adult Population (>14years)
  • Child Population (14years)

By Indication

  • Type 1 Diabetes
  • Type 2 Diabetes

By End User

  • Diagnostic/Clinics
  • ICUs
  • Home Healthcare

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Republic of South Africa
    • Saudi Arabia
    • Rest of LAMEA
 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets
3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year
3.2.2. Patent analysis by region
3.2.3. Patent analysis by product

3.3. GOVERNMENT REGULATIONS

3.3.1. U.S. FDA
3.3.2. Europe CE Mark
3.3.3. Ministry of Health, Labour, and Welfare (MHLW)

3.4. REIMBURSEMENT POLICIES
3.5. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.5.1. Smart contact lenses for glucose monitoring
3.5.2. iLet bihormonal bionic pancreas
3.5.3. Glucose nanosensors
3.5.4. Beta cell replacement therapy
3.5.5. Glucose-responsive insulin-producing cells

3.6. MARKET DYNAMICS

3.6.1. Drivers

3.6.1.1. Rise in incidence of diabetes
3.6.1.2. Rise in healthcare expenditure & disposable income
3.6.1.3. Benefits of using next generation diabetes products over conventional products

3.6.2. Restraints

3.6.2.1. Cost restrains
3.6.2.2. Lack of awareness
3.6.2.3. Less variability in products

3.6.3. Opportunities

3.6.3.1. Developing products with fewer side effects at affordable costs
3.6.3.2. High undiagnosed diabetic patient population
3.6.3.3. Tapping potential in developing regions

Chapter: 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,  BY PRODUCT

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INHALABLE INSULIN

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ORAL INSULIN

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. INSULIN PATCHES

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. CGMS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

Chapter: 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14YEARS)

5.2.1. Market size and forecast

5.3. CHILD POPULATION (≤14YEARS)

5.3.1. Market size and forecast

Chapter: 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. TYPE I DIABETES

6.2.1. Market size and forecast

6.3. TYPE II DIABETES

6.3.1. Market size and forecast

Chapter: 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. DIAGNOSTICS/CLINICS

7.2.1. Market size and forecast

7.3. ICUS

7.3.1. Market size and forecast

7.4. HOME HEALTHCARE

7.4.1. Market size and forecast

Chapter: 8 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY

8.1. OVERVIEW

8.1.1. Market size and forecast

8.2. NORTH AMERICA

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.2.3.1. U.S. market size and forecast
8.2.3.2. Canada market size and forecast
8.2.3.3. Mexico market size and forecast

8.3. EUROPE

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.3.3.1. Germany market size and forecast
8.3.3.2. UK market size and forecast
8.3.3.3. France market size and forecast
8.3.3.4. Italy market size and forecast
8.3.3.5. Spain market size and forecast
8.3.3.6. Rest of Europe market size and forecast

8.4. ASIA-PACIFIC

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

8.4.3.1. Japan market size and forecast
8.4.3.2. China market size and forecast
8.4.3.3. India market size and forecast
8.4.3.4. Australia market size and forecast
8.4.3.5. South Korea market size and forecast
8.4.3.6. Rest of Asia-Pacific market size and forecast

8.5. LAMEA

8.5.1. Key market trends
8.5.2. Key growth factors and opportunities
8.5.3. Market size and forecast

8.5.3.1. Brazil market size and forecast
8.5.3.2. Saudi Arabia market size and forecast
8.5.3.3. South Africa market size and forecast
8.5.3.4. Rest of LAMEA market size and forecast

Chapter: 9 COMPANY PROFILES

9.1. ABBOTT LABORATORIES

9.1.1. Company overview
9.1.2. Company snapshot
9.1.3. Operating business segments
9.1.4. Product portfolio
9.1.5. Business performance
9.1.6. Key strategic moves and developments

9.2. DEXCOM, INC.

9.2.1. Company overview
9.2.2. Company snapshot
9.2.3. Product portfolio
9.2.4. Business performance
9.2.5. Key strategic moves and developments

9.3. ECHO THERAPEUTICS, INC.

9.3.1. Company overview
9.3.2. Company snapshot
9.3.3. Operating business segments
9.3.4. Product portfolio
9.3.5. Business performance
9.3.6. Key strategic moves and developments

9.4. GLYSENS INCORPORATED

9.4.1. Company overview
9.4.2. Company snapshot
9.4.3. Operating business segments
9.4.4. Key strategic moves and developments

9.5. JOHNSON & JOHNSON

9.5.1. Company overview
9.5.2. Company snapshot
9.5.3. Operating business segments
9.5.4. Product portfolio
9.5.5. Business performance
9.5.6. Key strategic moves and developments

9.6. MANNKIND CORPORATION

9.6.1. Company overview
9.6.2. Company snapshot
9.6.3. Product portfolio
9.6.4. Key strategic moves and developments

9.7. MEDTRONIC PLC.

9.7.1. Company overview
9.7.2. Company snapshot
9.7.3. Operating business segments
9.7.4. Product portfolio
9.7.5. Business performance
9.7.6. Key strategic moves and developments

9.8. NOVO NORDISK A/S

9.8.1. Company overview
9.8.2. Company snapshot
9.8.3. Operating business segments
9.8.4. Product portfolio
9.8.5. Business performance

9.9. SANOFI

9.9.1. Company overview
9.9.2. Company snapshot
9.9.3. Operating business segments
9.9.4. Product portfolio
9.9.5. Business performance
9.9.6. Key strategic moves and developments

9.10. SENSEONICS HOLDINGS, INC.

9.10.1. Company overview
9.10.2. Company snapshot
9.10.3. Product portfolio
9.10.4. Business performance
9.10.5. Key strategic moves and developments

LIST OF TABLES

TABLE 1. RISE IN INCIDENCE OF DIABETES IN DIFFERENT GEOGRAPHICAL REGIONS: 2015 AND 2040 (MILLION)
TABLE 2. RISE IN HEALTHCARE EXPENDITURE IN DIFFERENT GEOGRAPHICAL REGIONS FROM 2015 TO 2040 ($BILLION)
TABLE 3. UNDIAGNOSED DIABETIC PATIENT POPULATION IN DIFFERENT GEOGRAPHICAL REGIONS IN 2015 (MILLION)
TABLE 4. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2014-2023 ($THOUSAND)
TABLE 5. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR INHALABLE INSULIN, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 6. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ORAL INSULIN, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 7. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR INSULIN PATCH, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 8. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR CGM SYSTEMS, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 9. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ARTIFICIAL PANCREAS, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 10. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($THOUSAND)
TABLE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ADULT POPULATION, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 12. TYPE-1 DIABETES (0–14 YEARS), 2015
TABLE 13. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR CHILD POPULATION, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 14. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($THOUSAND)
TABLE 15. NEXT GENERATION TYPE I DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 16. NEXT GENERATION TYPE II DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 17. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2014-2023 ($THOUSAND)
TABLE 18. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR DIAGNOSTIC/CLINICS, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ICUS, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 20. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR HOME HEALTHCARE, BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 21. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET,  BY GEOGRAPHY, 2014-2023 ($THOUSAND)
TABLE 22. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2014-2023 ($THOUSAND)
TABLE 23. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($THOUSAND)
TABLE 24. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($THOUSAND)
TABLE 25. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2014-2023 ($THOUSAND)
TABLE 26. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2014-2023 ($THOUSAND)
TABLE 27. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2014-2023 ($THOUSAND)
TABLE 28. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($THOUSAND)
TABLE 29. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($THOUSAND)
TABLE 30. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2014-2023 ($THOUSAND)
TABLE 31. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2014-2023 ($THOUSAND)
TABLE 32. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2014-2023 ($THOUSAND)
TABLE 33. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($THOUSAND)
TABLE 34. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($THOUSAND)
TABLE 35. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2014-2023 ($THOUSAND)
TABLE 36. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2014-2023 ($THOUSAND)
TABLE 37. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT, 2014-2023 ($THOUSAND)
TABLE 38. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($THOUSAND)
TABLE 39. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($THOUSAND)
TABLE 40. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USER, 2014-2023 ($THOUSAND)
TABLE 41. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2014-2023 ($THOUSAND)
TABLE 42. ABBOTT: COMPANY SNAPSHOT
TABLE 43. ABBOTT: OPERATING SEGMENTS
TABLE 44. ABBOTT: PRODUCT PORTFOLIO
TABLE 45. DEXCOM: COMPANY SNAPSHOT
TABLE 46. DEXCOM: PRODUCT PORTFOLIO
TABLE 47. ECHO THERAPEUTICS: COMPANY SNAPSHOT
TABLE 48. ECHO THERAPEUTICS: OPERATING SEGMENTS
TABLE 49. ECHO THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 50. GLYSENS: COMPANY SNAPSHOT
TABLE 51. GLYSENS: PRODUCT CATEGORY
TABLE 52. J&J: COMPANY SNAPSHOT
TABLE 53. J&J: OPERATING SEGMENTS
TABLE 54. J&J: PRODUCT PORTFOLIO
TABLE 55. MANNKIND: COMPANY SNAPSHOT
TABLE 56. MANNKIND: PRODUCT PORTFOLIO
TABLE 57. MEDTRONIC: COMPANY SNAPSHOT
TABLE 58. MEDTRONIC: OPERATING SEGMENTS
TABLE 59. MEDTRONIC: PRODUCT PORTFOLIO
TABLE 60. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 61. NOVO NORDISK: OPERATING SEGMENTS
TABLE 62. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 63. SANOFI: COMPANY SNAPSHOT
TABLE 64. SANOFI: OPERATING SEGMENTS
TABLE 65. SANOFI: PRODUCT PORTFOLIO
TABLE 66. SENSEONICS: COMPANY SNAPSHOT
TABLE 67. SENSEONICS: PRODUCT CATEGORIES

LIST OF FIGURES

FIGURE 1. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET: SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS, BY PRODUCT
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2017)
FIGURE 4. PATENT REGISTERED/APPROVED, BY YEAR
FIGURE 5. PATENT REGISTERED/APPROVED, BY REGION
FIGURE 6. PATENT REGISTERED/APPROVED, BY PRODUCT
FIGURE 7. ABBOTT: NET SALES, 2014-2016 ($MILLION)
FIGURE 8. ABBOTT: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 9. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 10. DEXCOM: NET SALES, 2014-2016 ($MILLION)
FIGURE 11. DEXCOM: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 12. ECHO THERAPEUTICS: NET SALES, 2013–2014 ($MILLION)
FIGURE 13. J&J: NET SALES, 2014-2016 ($MILLION)
FIGURE 14. J&J: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 15. J&J: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 16. MEDTRONIC: NET SALES, 2014-2016 ($MILLION)
FIGURE 17. MEDTRONIC: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 18. MEDTRONIC: REVENUE SAHRE BY GEOGRAPHY, 2016 (%)
FIGURE 19. NOVO NORDISK: NET SALES, 2014-2016 ($MILLION)
FIGURE 20. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 21. NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 22. SANOFI: NET SALES, 2014-2016 ($MILLION)
FIGURE 23. SANOFI: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. SANOFI: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 25. SENSEONICS: NET SALES, 2015-2016 ($THOUSAND)

 

The demand for oral & inhalable insulin has increased as these are painless mode of insulin delivery and reduce the risk of skin irritation caused due to needles. They are expected to replace injectable insulins, owing to their ease of using with improved efficiency. Furthermore, these insulins help to improve the adherence to medication, thus providing better diabetes management.

Advancement in diabetic therapy systems, such as insulin patches and artificial pancreas, the amount of insulin that needs to be introduced into the patients’ body is adjusted according to the blood sugar levels that uses a computer algorithm. The automated version of these systems is expected to help the patient to reduce the complications related to hypo- or hyperglycemia. For instance, Medtronic’s MiniMed 670G system was the first artificial pancreas that detects the blood glucose level of the patient and adjusts the delivery of insulin as per the sensor glucose values. Such advancement in diabetic technology is expected to increase the market growth exponentially.

The employment of technologically advanced products is highest in North America, owing of the increase in adoption of these products and increase in disposable income among patients. Rise in disposable income, growth in healthcare expenditure in the developing countries, such as China and India, and increase in the adoption of advanced diabetic products contribute toward market growth in the Asia-Pacific region, accounting for the highest growth rate.

 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 

Request Sample

Request Customization

Request sample

OR

Purchase Full Report of
Next Generation Diabetes Therapy and Drug Delivery Market- Global Opportunity Analysis and Industry Forecast, 2014-2023

  • Online Only
  • $4176
  • Online cloud Access only
  • Restricted Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprise
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Access reports on all emerging
market of Life Sciences on Knowledge Tree Platform
Free Demo